Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message| ()  

Do you value the buying and selling trends of smart money institutional managers? We ran a screen with that idea in mind.

We began by screening the healthcare sector for stocks that have outperformed the market over the last quarter, with over 20% quarterly return.

We then screened for those with bearish sentiment from institutional investors, with significant net institutional sales over the last quarter representing at least 5% of share float. This indicates that institutional investors such as hedge fund managers and mutual fund managers expect these names to underperform in the future.

For an interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research.

Tool provided by Kapitall. More investing ideas on Kapitall Wire.

Do you think these stocks are vulnerable to a pullback? Use this list as a starting point for your own analysis.

List sorted by net institutional sales as a percent of share float.

1. Celsion Corp. (CLSN): Develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. Market cap at $100.02M, most recent closing price at $3.03. Performance over the last quarter at 52.79%. Net institutional sales in the current quarter at 3.4M shares, which represents about 11.79% of the company's float of 28.85M shares.

2. United Therapeutics Corporation (UTHR): Engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and Internationally. Market cap at $2.87B, most recent closing price at $55.62. Performance over the last quarter at 28.76%. Net institutional sales in the current quarter at 4.9M shares, which represents about 10.25% of the company's float of 47.80M shares.

3. Tranzyme, Inc. (TZYM): Focuses on discovering, developing, and commercializing small molecule therapeutics for the treatment of acute and chronic gastrointestinal (GI) motility disorders in the United States and internationally. Market cap at $104.35M, most recent closing price at $4.24. Performance over the last quarter at 48.25%. Net institutional sales in the current quarter at 740.3K shares, which represents about 10.17% of the company's float of 7.28M shares.

4. Select Medical Holdings Corporation (SEM): Operates specialty hospitals and outpatient rehabilitation clinics in the United States. Market cap at $1.67B, most recent closing price at $12.88. Performance over the last quarter at 30.40%. Net institutional sales in the current quarter at 3.0M shares, which represents about 8.9% of the company's float of 33.72M shares.

5. Endocyte, Inc. (ECYT): Engages in developing targeted therapies for the treatment of cancer and inflammatory diseases. Market cap at $324.71M, most recent closing price at $8.99. Performance over the last quarter at 26.71%. Net institutional sales in the current quarter at 1.9M shares, which represents about 7.69% of the company's float of 24.72M shares.

6. Cadence Pharmaceuticals Inc. (CADX): Focuses on in-licensing, developing, and commercializing product candidates principally for use in the hospital setting in the United States and Canada. Market cap at $337.88M, most recent closing price at $3.95. Performance over the last quarter at 36.21%. Net institutional sales in the current quarter at 3.1M shares, which represents about 5.49% of the company's float of 56.51M shares.

7. Keryx Biopharmaceuticals Inc. (KERX): Focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Market cap at $131.7M, most recent closing price at $1.90. Performance over the last quarter at 31.21%. Net institutional sales in the current quarter at 3.6M shares, which represents about 5.19% of the company's float of 69.43M shares.

*Institutional data sourced from Fidelity, all other data sourced from Finviz.

Source: 7 Outperforming Healthcare Stocks Being Sold By Hedge Fund Managers